Leverage is minimal with total debt of $9.4M against $391.2M of equity (debt-to-equity 0.02), yet the accumulated deficit of -$351.9M and a shrinking equity base suggest the capital cushion is being steadily consumed by clinical spend.
Rapport Therapeutics, Inc. Common Stock (RAPP) balance sheet — 4-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 |
|---|
| Total Current Assets | 407.38M | 498.56M | 309.8M | 150.87M | 31.27M |
| Cash & Short-Term Investments | 395.03M | 490.54M | 305.28M | 147.48M | 31.16M |
| Cash Only | 74.75M | 52.65M | 56.8M | 70.17M | 31.16M |
| Short-Term Investments | 320.27M | 437.89M | 248.47M | 77.31M | 0 |
| Accounts Receivable | 171K | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 2.38 | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 105K | 8.02M | 4.52M | 3.39M | 0 |
| Total Non-Current Assets | 11.18M | 13.87M | 5.13M | 4.55M | 335K |
| Property, Plant & Equipment | 10.08M | 12.88M | 4.97M | 4M | 335K |
| Fixed Asset Turnover | 1.74x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.09M | 985K | 160K | 551K | 0 |
| Total Assets | 418.56M | 512.43M | 314.93M | 155.42M | 31.6M |
| Asset Turnover | 0.04x | - | - | - | - |
| Asset Growth % | 166.4% | 62.71% | 102.63% | 391.8% | - |
| Total Current Liabilities | 20.3M | 19.05M | 8.77M | 8.8M | 1.66M |
| Accounts Payable | 1.72M | 4.19M | 1.95M | 2.5M | 1.45M |
| Days Payables Outstanding | - | - | - | - | 35.28K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 7.12M | 3.71M | 2.41M | 0 |
| Current Ratio | 20.07x | 26.17x | 35.34x | 17.14x | 18.80x |
| Quick Ratio | 20.07x | 26.17x | 35.34x | 17.14x | 18.80x |
| Cash Conversion Cycle | 2.38 | - | - | - | - |
| Total Non-Current Liabilities | 7.07M | 8.73M | 739K | 172.25M | 10.44M |
| Long-Term Debt | 0 | 8.73M | 0 | 0 | 10.44M |
| Capital Lease Obligations | 14.7M | 0 | 739K | 1.48M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 170.78M | 0 |
| Total Liabilities | 27.37M | 27.78M | 9.51M | 181.06M | 12.1M |
| Total Debt | 9.39M | 11.48M | 1.48M | 2.15M | 10.44M |
| Net Debt | -65.36M | -41.16M | -55.33M | -68.02M | -20.72M |
| Debt / Equity | 0.02x | 0.02x | 0.00x | - | 0.53x |
| Debt / EBITDA | -0.06x | - | - | - | - |
| Net Debt / EBITDA | 0.39x | - | - | - | - |
| Interest Coverage | - | - | - | - | -36.38x |
| Total Equity | 391.19M | 484.65M | 305.43M | -25.63M | 19.5M |
| Equity Growth % | 160.6% | 58.68% | 1291.49% | -231.42% | - |
| Book Value per Share | 8.19 | 12.45 | 14.73 | -17.02 | 0.97 |
| Total Shareholders' Equity | 391.19M | 484.65M | 305.43M | -25.63M | 19.5M |
| Common Stock | 48K | 48K | 37K | 4K | 31K |
| Retained Earnings | -351.94M | -235.23M | -123.75M | -45.44M | -10.65M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.12M | 546K | -522K | 4K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying RAPP stock.
As of 2025, Rapport Therapeutics, Inc. Common Stock (RAPP) had total assets of $512.4M including $498.6M in current assets.
Rapport Therapeutics, Inc. Common Stock (RAPP) carries total debt of $11.5M, offset by $490.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Rapport Therapeutics, Inc. Common Stock (RAPP) has total shareholders' equity (book value) of $484.7M ($12.45 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Rapport Therapeutics, Inc. Common Stock (RAPP) reported a current ratio of 26.17x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Dilution dependence through pivotal trials
Metrics are mathematically derived from official filings.
Equity Base Shrinking as Losses Accumulate
According to reported balance sheet figures, RAPP's total equity fell from $423M in 2025Q4's neighbor 2026Q2 level to $391.2M in 2026Q3 as accumulated deficit deepened to -$351.9M, signaling steady erosion of the capital base.
The balance sheet appears to be weakening rather than strengthening, with equity declining in each of the most recent quarters while the accumulated deficit widens in step with R&D-driven losses. This pattern suggests the company is consuming its equity cushion faster than it can be replenished through operations, which is expected for a pre-revenue firm but still warrants monitoring of how much runway remains before the next capital raise. Investors should watch whether the decline continues at the pace implied by the recent quarterly losses.
Thin Cash Cushion Against Quarterly Burn
As reported in the financial statements, RAPP held $74.8M in cash at 2026Q3 against an operating cash outflow of $41.6M in the same quarter, implying coverage of only about two quarters at current burn rates.
The current ratio of 20.07 looks strong on the surface, but it is driven by a largely liquid asset base that is being drawn down rapidly by clinical spending rather than reflecting durable financial strength. The cash position relative to quarterly outflows suggests limited tolerance for trial delays or cost overruns. This may indicate that a financing event is a plausible near-term outcome rather than a remote contingency.
Minimal Leverage Keeps Solvency Risk Low
Based on reported figures, RAPP carries total debt of just $9.4M against $391.2M of equity, producing a debt-to-equity ratio of 0.02 that leaves the company largely insulated from creditor pressure.
Leverage is negligible and appears deliberate, consistent with an equity-funded development model rather than a necessity-driven borrowing pattern. Because debt is so small, refinancing risk is minimal and near-term solvency is not the binding constraint. The real pressure point is equity funding, not debt service, which shifts the risk toward dilution.
Accumulated Deficit Signals Dilution Path
According to reported equity figures, retained earnings stood at -$351.9M in 2026Q3, and the company's reliance on external capital means shareholders should expect further issuance as pivotal trial costs ramp.
The deepening accumulated deficit reflects the cumulative cost of clinical development rather than any recurring value leakage, but it also means the equity base is being funded almost entirely by outside capital. Continued losses of roughly $40M per quarter imply that additional share issuance is a likely path, with corresponding dilution for existing holders. Stock-based compensation of around $7.6M per quarter adds a further non-cash claim on equity that investors should factor into per-share economics.
Headline Cash Overstates Usable Runway
Based on reported figures, the balance sheet may look more secure than the cash burn warrants, since $74.8M in cash measured against recent quarterly outflows of $41.6M suggests the effective runway could be shorter than headline liquidity implies.
The most non-obvious distortion is that a strong current ratio and near-zero leverage can mask a short effective runway, because the liquid assets are small relative to the pace of clinical spending. Cash balances also swing meaningfully quarter to quarter, as seen in the drop from $251.4M in 2025Q3 to $52.6M in 2025Q4, which indicates that reported liquidity levels can change sharply. Analysts should therefore treat the balance sheet as adequate only until the next financing, not as a durable buffer.